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Introduction: As there is little information on the histologic char-
acteristics of adenocarcinoma in smokers, we histologically exam-
ined the effect of smoking on the carcinogenesis and progression of
peripheral small lung adenocarcinomas.
Methods: Two hundred thirty-six consecutive patients with periph-
eral adenocarcinoma of the lung 30 mm or less in diameter were
studied. Prognosis, histology, and location of the adenocarcinoma
were compared among patients with a Brinkman index (B.I.) of 0, 1
to 500, and more than 500.
Results: The ratio of smokers to nonsmokers was 1.4:1. The rate of
carcinogenesis in the upper region of the lung (S1-3) was 1.4 times
as high that in the lower region (S4-10) in smokers, but almost equal
in the two regions in nonsmokers. Outcome tended to be worse in
patients with a B.I. of more than 500 than in those with a B.I. of less
than or equal to 500 for adenocarcinomas 30 mm or less in diameter
(p  0.0855), and was significantly worse for adenocarcinomas 20
mm or less in diameter (p  0.0359). Patients with a high B.I.
tended to have invasive adenocarcinoma (IAC) without a bronchi-
oloalveolar carcinoma (BAC) component (IAC  BAC) or IAC
with a BAC component (IAC  BAC) rather than noninvasive
adenocarcinoma. For adenocarcinomas as a whole, B.I. was corre-
lated with several pathologic prognostic factors, including patho-
logic stage, lymphatic permeation, vascular invasion, presence of a
solid component, necrosis, and modified scar grade, particularly in
the upper region. Specifically, in IAC  BAC, B.I. was correlated
with modified scar grade and the presence of a solid component. In
IAC  BAC, B.I. was correlated with the presence of a solid
component and necrosis.
Conclusions: Small adenocarcinoma in smokers seems to occur
frequently in the upper region of the lung, shows invasive features
more frequently, and shows greater progression and dedifferentia-
tion than that in nonsmokers. Tobacco-smoking may have an effect
on the carcinogenesis and multistep progression of peripheral lung
adenocarcinoma 30 mm or less in diameter.
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Among several histologic types of lung carcinoma, a grad-ual increase in the incidence of peripheral adenocarci-
noma has been reported,1,2 although the effect of smoking on
the carcinogenesis and progression of peripheral adenocarci-
noma is unclear. The relative risk for lung cancer among
smokers over nonsmokers is reported to be 2 to 10 for
adenocarcinoma, and more than 10 for squamous cell carci-
noma and small cell carcinoma.3 Squamous cell carcinoma
and small cell carcinoma tend to occur in the upper lobe,4–8
but there have been few reported studies on the location of
adenocarcinoma.8,9
Several studies have indicated that the prognosis of
adenocarcinoma10–12 or nonsmall nonsquamous cell carcino-
ma13 in smokers is worse than that in nonsmokers. Suzuki
et al.14 and Morita and Urano15 reported that the incidence of
moderately to poorly differentiated adenocarcinoma was
higher in smokers than in nonsmokers, but no detailed histo-
logic study has yet examined the relationship between smok-
ing status and histologic changes in these cancers.
With regard to the progression of lung adenocarcinoma,
Shimosato et al.16 and Clayton17 indicated that bronchioloal-
veolar carcinoma might progress to mixed subtypes with a
BAC component ( sclerosing bronchioloalveolar carci-
noma). On the other hand, papillary, acinar, solid adenocar-
cinoma, and mixed subtypes without a BAC component were
considered to be de novo carcinoma,18 or a progressed form
of mixed subtypes with a BAC component.
In the present study, we pathologically examined the
effect of smoking on the carcinogenesis and progression of
peripheral small lung adenocarcinoma, with reference to
tumor location.
PATIENTS AND METHODS
We reviewed 236 consecutive patients with peripheral
lung adenocarcinomas 30 mm or less in diameter, who
underwent lobectomy at the National Cancer Center Hospital
between 1984 and 1990. Peripheral lung adenocarcinoma was
defined as a tumor located in a fourth branching bronchus or
more peripheral region. Recently, now that the prevalence of
smoking is decreasing, the incidence of adenocarcinoma with
a predominantly bronchioloalveolar carcinoma (BAC) com-
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ponent has been increasing and that of invasive adenocarci-
noma (IAC) without a BAC component (IAC  BAC) has
been decreasing. Therefore, to examine the relationship of
smoking to invasiveness of adenocarcinoma, we selected the
period when the prevalence of smoking and the incidence of
overt IAC were relatively high. Clinical information was
extracted from medical records. Tumor, node, metastasis
staging was determined in accordance with the Union Inter-
nationale Contre le Cancer (International Union Against Can-
cer) staging system.19 Tumor location was classified as the
upper region (lung segments 1–3) or lower region (segments
4–10). Noninvasive adenocarcinoma (NAC) was defined as
pure BAC without a desmoplastic reaction.
Survival rates of patients divided into three Brinkman
index (B.I.) groups (B.I. 0, 1–500, and 500) were com-
pared, and the distribution of NAC, IAC with a BAC com-
ponent (IAC  BAC) and IAC  BAC in each B.I. group
was analyzed. Correlations between B.I. and several patho-
logic prognostic factors (pathologic (p) stage, pT, pN, pleural
invasion, lymphatic permeation (ly), vascular invasion (v),
presence of papillary, acinar or solid component, necrosis,
and modified scar grade (MSG)20) were examined. MSG is
one of the prognostic factors for small lung adenocarcinoma,
evaluated according to the structure and size of the central
scar of adenocarcinoma, being a modification of the scar
grade proposed by Shimosato et al.16 When the p value was
less than 0.10, the same examination was performed for
tumors in the upper region and lower region, respectively.
Survival rates of each B.I. group were compared for
adenocarcinoma with a BAC component (NAC and
IAC  BAC), IAC  BAC, and IAC  BAC, respectively.
In IAC  BAC and IAC  BAC, prognostic factors that
were correlated with B.I. were extracted.
The patients were followed up extensively, and the
follow-up period ranged from 1 to 204 months, with a median
of 84 months. Patients who died of causes other than lung
adenocarcinoma were censored at the last follow-up. The 5-
and 10-year survival rates were calculated by the Kaplan-
Meier method. Correlations of B.I. with several pathologic
factors were examined by the Mann-Whitney U test or
Spearman coefficient test. When the p value was less than
0.05, differences were considered significant, and when be-
tween 0.05 and 0.10, we considered that there was a tendency
for a difference.
RESULTS
The patients comprised 144 men and 92 women, rang-
ing in age from 26 to 84 years with a median of 60 years.
Among the 236 patients, 142 were classified as p stage IA, 8
as stage IB, 13 as stage IIA, 7 as stage IIB, 39 as stage IIIA,
20 as stage IIIB, and 7 as stage IV. Tumors were smaller than
20 mm in 112 cases and 20 to 30 mm in 124 cases. Lymph
node metastasis was present in 77 cases (33%), ly in 117
cases (50%), v in 120 cases (51%), and pleural involvement
(p2–3) in 49 cases (23%). Pleural involvement was defined as
p0: no invasion of the visceral pleura, p1: invasion beyond
the elastic framework of the visceral pleura, p2: exposure to
the thoracic cavity, and p3: invasion to the parietal pleura,
mediastinum, or diaphragm.
The ratio of smokers to nonsmokers was 1.4:1 (139:97
patients). Correlations between B.I. and presence of a
BAC component and invasion are shown in Table 1. As the
B.I. increased, NAC decreased and IAC  BAC and
IAC  BAC increased (Table 1). The BAC component was
FIGURE 1. Survival curves for each
B.I. group in patients with lung ade-
nocarcinoma. A, Tumors 30 mm or
less in diameter. B, Tumors 20 mm
or less in diameter.
TABLE 1. Relationship Between B.I. and Presence of a BAC
Component and Invasion
Smoking Habit
B.I.  0
(n  97)
B.I. 1–500
(n  30)
B.I. > 500
(n  109)
Spearman
Coefficient (p)
Histology
NAC (n  28) 17 (61%) 4 (14%) 7 (25%) 0.0001
IAC  BAC
(n  139)
63 (46%) 20 (14%) 56 (40%)
IAC  BAC
(n  69)
17 (25%) 6 (9%) 46 (66%)
B.I., Brinkman index; BAC, bronchioloalveolar carcinoma; NAC, noninvasive
adenocarcinoma; IAC  BAC, invasive adenocarcinoma with a BAC component;
IAC  BAC, invasive adenocarcinoma without a BAC component.
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the nonmucinous type (Clara/type II) in most cases (165/167)
and mucinous type in two. The ratio of the number of tumors
in the upper region to that in the lower region was 1.2:1
(129:107 tumors). A higher rate of carcinogenesis in the
upper region to lower region was detected in smokers (1.4
times, 81:58 tumors), but almost equal in the two regions in
nonsmokers (48:49 tumors).
The group with B.I. of more than 500 tended to have a
worse outcome than the group with B.I. of less than or equal
to 500 for adenocarcinomas 30 mm or less in diameter (p 
0.0855, Figure 1A), and had a significantly worse outcome for
adenocarcinomas 20 mm or less in diameter (p  0.0359,
Figure 1B). The respective 5- and 10-year survival rates were
77.6 and 66.0% in the group with B.I. of 500 or less, and 66.3
and 59.6% in the group with B.I. of more than 500 for
adenocarcinomas 30 mm or less in diameter. The respective
5- and 10-year survival rates were 81.5 and 73.6% in the
group with B.I. of 500 or less, and 63.0 and 59.8% in the
group with B.I. of more than 500 for adenocarcinomas 20 mm
or less in diameter. Outcomes did not differ between men and
women for adenocarcinomas 30 mm or less in diameter and
20 mm or less in diameter.
For adenocarcinoma as a whole, the correlations of B.I.
with several pathologic prognostic factors we have reported
TABLE 2. Relationship Between B.I. and Clinicopathologic Prognostic Factors in
Adenocarcinoma 30 mm or Less in Diameter
No. of cases B.I.
(0/1–500/>500)
5-yr
Survival (%)
Mann-Whitney U
Test p*
p† for Upper (U)
and Lower (L) Region
Total 97/30/109 72.7
p Stage
Stage I 67/19/64 91.8 0.0761 U: ns
Stage II–IV 30/11/45 35.5 L: ns
pT
T1 76/22/89 83.6 ns
T2–4 21/8/20 33.3
pN
N0 71/19/69 79.6 ns
N1–3 26/11/40 25.8
Pleural invasion
p 0–1 76/22/89 74.6 ns
p 2–3 21/8/20 21.6
Lymphatic permeation
Negative 56/14/49 82.9 0.0486 U: 0.0848
Positive 34/17/66 41.1 L: ns
Vascular invasion
Negative 53/13/50 75.6 0.0376 U: 0.0858
Positive 39/19/62 48.3 L: ns
Papillary component
Absent 21/8/32 84.0 ns
Present 76/22/77 68.7
Acinar component
Absent 49/15/48 79.5 ns
Present 48/15/61 65.5
Solid component
Absent 73/18/52 78.5 0.0001 U: 0.0002
Present 24/12/57 62.7 L: 0.0692
Necrosis
Absent 76/22/73 76.2 0.0544 U: ns
Present 21/8/36 61.9 L: ns
Modified scar grade
Grade 1 17/4/8 100
Grade 2 31/8/21 91.9 ] 0.0002 U: 0.0001
Grade 3 28/10/39 65.4 L: ns
Grade 4 21/8/41 51.9 ]
]
*Mann-Whitney U test p value for relationship between B.I. and pathologic factors.
†Mann-Whitney U test p value for upper (U) region and lower (L) region.
ns: not significant or no tendency (p  0.1).
B.I.: Brinkman index.
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previously20 are shown in Table 2. In our previous study, a
papillary, acinar or solid component, necrosis, and MSG were
prognostic factors, and some conventional prognostic factors
including p stage, pT, pN, pleural invasion, ly, and v. In the
present study, correlations of B.I. with some of these factors
including p stage, ly, v, presence of a solid component,
necrosis, and MSG were detected. The correlations with ly, v,
presence of a solid component, and MSG were strong for
tumors in the upper region.
As we considered that carcinogenesis and progression
might differ in each B.I. group, a further study was per-
formed. Adenocarcinoma with a BAC component (NAC and
IAC  BAC) was slightly dominant in males and smokers;
the male:female ratio was 1.7:1 (89:77 cases), and the num-
bers of tumors in the B.I. 0, 1 to 500, and more than 500
groups were 80, 24, and 63, respectively. However, when
limited to NAC, the incidence of females and nonsmokers
was high; the male:female ratio was 1:1.6 (11:17 cases) and
the numbers of tumors in the respective B.I. groups were 17,
4, and 7, respectively. For adenocarcinomas with a BAC
component (NAC and IAC  BAC) 30 mm or less in diam-
eter, the group with B.I. of more than 500 tended to have a
worse outcome than the group with B.I. of less than or equal
to 500 (p 0.0729, Figure 2A), and this was also the case for
adenocarcinomas 20 mm or less in diameter (p  0.0661,
Figure 2B). When limited to IAC  BAC, no significant
difference in outcome was detected between the group with
B.I. of 500 or less and the group with B.I. of more than 500,
but B.I. was correlated with the presence of a solid compo-
nent and MSG, particularly in the upper region (Table 3).
IAC  BAC was dominant in males and heavy smok-
ers; the male:female ratio was 1:2.9 (18:51 cases) and the
numbers of tumors in the B.I. 0, 1 to 500, and more than 500
groups were 17, 6, and 46, respectively. Although the sur-
vival rate did not differ significantly between the groups with
B.I. of less than or equal to 500 and more than 500, B.I. and
the presence of a solid component and necrosis were posi-
tively correlated, and B.I. and the presence of an acinar
component showed a negative correlation, particularly in the
upper region.
DISCUSSION
We reviewed 236 cases of peripheral lung adenocarci-
noma 30 mm or less in diameter and examined some aspects
of their carcinogenesis and progression pathologically. The
relative risk for lung cancer among smokers compared with
nonsmokers is reported to be 2 to 10 for adenocarcinoma.3
Our results were similar, as smokers were dominant; non-
smoker:smoker ratio was 1:1.4. It is well known that lung
cancer, especially squamous cell carcinoma and small cell
carcinoma, occurs frequently in the upper region of the lung
among smokers or individuals with asbestos exposure, be-
cause transairway carcinogens persist longer in the upper lobe
owing to the lower ventilation rate and less efficient lym-
phatic clearance.4–9 Our study showed that the carcinogenesis
rate was higher in the upper region than in the lower region
in smoker, suggesting that tobacco-smoking affected carci-
nogenesis of small adenocarcinoma in the upper region.
As the B.I. increased, NAC decreased and IAC  BAC
and IAC  BAC increased, suggesting that NAC might
progress to IAC  BAC, and thereafter to IAC  BAC, as a
result of smoking.
The group with B.I. of more than 500 tended to have a
worse outcome than the group with B.I. of less than or equal
to 500. It has been reported that smoking is a poor prognostic
factor in patients with lung adenocarcinoma11 or stage I lung
adenocarcinoma.12 Shiba et al. reported that in patients with
nonsmall, nonsquamous cell carcinoma, heavy smokers (30
pack-years) had a significantly worse prognosis than lighter
smokers (0–30 pack-years) for overall stage and also stage
I.13 We only examined cases of definite adenocarcinoma, and
found that the survival rate tended to be different between the
group with B.I. of more than 500 and group with B.I. of 0 to
500 in adenocarcinomas 30 mm or less in diameter (p 
0.0855), whereas it was significantly different for adenocar-
cinomas 20 mm or less in diameter (p  0.0359), suggesting
that the degree of smoking affects the prognosis of lung
adenocarcinoma. Several reasons why p values differed be-
tween adenocarcinomas 30 mm or less in diameter and those
20 mm or less in diameter were speculated that a prognostic
FIGURE 2. Survival curves for each
B.I. group in patients with adeno-
carcinoma with a BAC component.
A, Tumors 30 mm or less in diame-
ter. B, Tumors 20 mm or less in
diameter.
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difference was only detected in adenocarcinomas smaller
than 20 mm, but was not significant for large and more
progressed tumors, or that smoking was a mildly influential
prognostic factor so that the p value did not constantly
indicate significance.
We examined the correlations of B.I. with several
pathologic prognostic factors for adenocarcinoma as a whole,
and found that ly, v, presence of a solid component, necrosis,
and MSG were correlated. Because these correlations were
strong in the upper region of the lung, adenocarcinoma might
progress and dedifferentiate predominantly in the upper re-
gion as a result of smoking. In adenocarcinoma with a BAC
component, the group with B.I. of more than 500 tended to
have a poorer outcome than the group with B.I. of less than
or equal to 500, and in IAC  BAC, B.I. correlated with
MSG and the presence of a solid component, suggesting that
the degree of smoking affects tumor progression in adeno-
carcinoma with a BAC component. In IAC  BAC, which is
considered to be de novo carcinoma or a progressed form of
adenocarcinoma with a BAC component, outcome did not
differ between the group with B.I. of 500 or less and the
group with B.I. of more than 500. Nevertheless, a detailed
examination revealed that an acinar component was predom-
inant in the group with B.I. of 500 or less, whereas a solid
TABLE 3. Relationship Between B.I. and Clinicopathologic Prognostic Factors in IAC  BAC and IAC  BAC
IAC  BAC
No. of Case B.I.
(0/1–500/>500)
Mann-Whitney
U Test p*
p† for U and
L Region
IAC  BAC
No. of Case B.I.
(0/1–500/>500)
Mann-Whitney
U Test p*
p† for U and
L Region
Total (139)
p Stage
Stage I 40/12/32 ns 10/3/2 ns
Stage II–IV 23/8/24 7/3/21
pT
T1 44/14/43 ns 15/4/39 ns
T2–4 19/6/13 2/2/7
pN
N0 43/12/34 ns 11/3/28 ns
N1–3 20/8/22 6/3/18
Pleural invasion
p 0–1 44/14/43 ns 15/4/39 ns
p 2–3 19/6/13 2/2/7
Lymphatic permeation
Negative 34/8/21 ns 10/3/18 ns
Positive 29/12/35 7/3/28
Vascular invasion
Negative 33/7/26 ns 6/1/16 ns
Positive 30/13/30 11/5/30
Papillary component
Absent 8/4/10 ns 4/4/16 ns
Present 55/16/46 13/2/30
Acinar component
Absent 31/11/22 ns 2/0/19 0.0011 U: 0.0032‡
Present 32/9/34 15/6/27 L: ns
Solid component
Absent 47/12/30 0.0135 U: 0.0144 9/2/15 0.0964 U: ns
Present 16/8/26 L: ns 8/4/31 L: ns
Necrosis
Absent 44/15/44 ns 15/3/22 0.0217 U: 0.0842
Present 19/5/12 2/3/24 L: ns
Modified scar grade
Grade 1 — 0/0/1
Grade 2 29/7/17 0.0518 U: ns 2/1/4 ] ns
Grade 3 18/7/21 ] L: ns 10/3/18
Grade 4 16/6/18 ] 5/2/23 ]
]
*Mann-Whitney U test p value for relationship between B.I. and pathologic factors.
†Mann-Whitney U test p value for upper (U) region and lower (L) region.
‡Acinar component present frequently in low B.I. patients, particularly in upper region.
ns, not significant or no tendency (p  0.1); B.I., Brinkman index; BAC, bronchioloalveolar carcinoma; NAC, noninvasive adenocarcinoma; IAC  BAC, invasive
adenocarcinoma with a BAC component; IAC  BAC, invasive adenocarcinoma without a BAC component.
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component and necrosis was predominant in the group with
B.I. of more than 500. We considered that the mechanism of
progression might differ according to the degree of smoking,
and that smokers tended to have a dedifferentiated compo-
nent. Previously, it has been suggested that lung adenocarci-
noma in smokers is progressed or has special characteristics
on the basis of immunohistochemical or molecular biological
examinations, exhibiting a high Ki-67 labeling index,13 a high
frequency of K-ras21–24 or p53 mutation,23,24 a low frequency
of epidermal growth factor receptor (EGFR) mutation,22 a
high incidence of loss of heterozygosity,25 and a high fre-
quency of p53 mutation with transversion pattern.26
In conclusion, small adenocarcinoma in smokers seems
to occur frequently in upper region, have more frequent
invasive features, and be much more progressed and dedif-
ferentiated than that in nonsmokers, predominantly in the
upper region of the lung. Tobacco-smoking may have an
effect on the carcinogenesis and multistep progression of
peripheral lung adenocarcinoma 30 mm or less in diameter,
particularly in the upper region.
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